Scientists at UCLA's Jonsson Cancer Center, working to define the genetic profile of AIDS-related lymphomas, have identified a gene they believe may be linked to non-Hodgkin's lymphoma in AIDS patients.
A team of UCLA scientists has discovered two human proteins that inhibit the formation of new blood vessels and have potential for treating cancer through suppression of tumor growth.
Aggressive surgery coupled with strong immunotherapy resulted in significantly increased survival times for a group of advanced kidney cancer patients for whom few other treatment options existed, according to researchers at UCLA's Jonsson Cancer Center.
An experimental genetic treatment has yielded promising results for some women whose disease failed to respond to conventional treatments, according to a preliminary study at UCLA's Jonsson Cancer Center.
The human thymus -- the organ that produces the immune system's infection-fighting T cells -- remains functional until at least age 56, UCLA AIDS Institute investigators have proved for the first time.
Promising results for a vaccine to treat brain cancer in preliminary studies at UCLA's Jonsson Cancer Center was reported in the cover-story published in the June 1 issue of the Journal of Neurosurgery.
Five Los Angeles-area health centers will be among 400 sites to offer a drug that may reduce the risk of breast cancer in postmenopausal women. The Study of Tamoxifen and Raloxifene, or STAR, is one of the largest breast cancer prevention studies ever conducted, and will involve 22,000 women at sites in the United States, Canada and Puerto Rico.
Owning a pet may reduce the likelihood that men with AIDS will suffer from depression, according to a study by researchers at the UCLA School of Public Health.
Adults who suffer from obstructive sleep apnea are three times more likely to also have diabetes, according to a new UCLA School of Dentistry/Department of Veterans Affairs study published in the Journal of Oral and Maxillofacial Surgery.
Children who live through catastrophic events develop an advanced understanding of right and wrong, but they may not act morally because the trauma disrupts their view of the world, according to researchers from the UCLA School of Medicine.
Researchers at UCLA's Jonsson Cancer Center today are launching a new experimental treatment for advanced colon cancer, using a drug thought to attack tumors by cutting off their blood supply. UCLA is the only site worldwide offering this experimental treatment for colon cancer, researchers said.
Researchers at UCLA's Jonsson Cancer Center today (Feb. 22) began a new experimental treatment that targets a genetic mutation found in about 90 percent of pancreatic cancer cases. UCLA is the only site in Southern California to offer the new therapy.
Ethnicity plays no role in determining quality of life for long-term breast cancer survivors, according to a first-of-its-kind study led by researchers from UCLA's Jonsson Cancer Center. Sociological factors such as life stress, relationship status, education and income, however, do affect how well women cope after having the disease, the study found.
UCLA becomes a new friend for man's best friends as the university's Department of Radiation Oncology and local veterinarians join forces to provide radiation therapy exclusively for dogs and cats with cancer.
New treatments for men with metastatic prostate cancer could develop from a discovery made by a research team at UCLA's Jonsson Cancer Center. The treatments would involve shutting down a pathway that can carry excessive growth signals to prostate cells, thereby causing prostate cancer.
Oncology physicians and nurses at UCLA's Jonsson Cancer Center will experience the extreme fatigue their patients feel during a unique training session Monday, Oct. 26, using a virtual reality simulator that lets health care workers walk in a cancer patient's shoes.
Physicians at UCLA's Jonsson Cancer Center today launched a new experimental treatment for inoperable pancreatic cancer using a form of a virus that causes the common cold.
The breakthrough breast cancer drug Herceptin was approved late Friday by the U.S. Food and Drug Administration, the first in an expected wave of new therapies that will attempt to beat back cancer by attacking the disease at its genetic roots. Herceptin was developed in a joint effort of UCLA's Jonsson Cancer Center and the biotechnology company Genentech, Inc., of South San Francisco.
Calling it the most significant advance in radiosurgery technology in a decade, physicians at UCLA's Jonsson Cancer Center today opened the first facility in the US offering BrainLAB's Novalis -- a shaped beam surgery system designed to treat brain tumors.
The first custom sacrum prosthetic implant operation of its kind in the United States has been successfully performed by three UCLA doctors. The doctors have successfully rejoined a patient's pelvis to her lumbar spine with an innovative prosthetic device produced by Howmedica, Inc., of Rutherford, New Jersey. The doctors implanted a prosthesis in the patient, a 49-year-old woman (Tulare, Calif.) whose sacrum -- known as the tailbone -- had been destroyed by a giant cell tumor.
An advisory panel for the U.S. Food and Drug Administration (FDA) today recommended approval of the breast cancer drug Herceptin, the first cancer drug to successfully treat a specific genetic alteration. The FDA's Oncologic Drugs Advisory Committee recommended Herceptin for approval as a single agent and in combination with Taxol.
UCLA Medical Center's Heart Transplant Program announced on May 5 that it has reached a collaborative agreement to begin training its surgeons and staff to install a battery-powered artificial heart replacement device developed and manufactured by ABIOMED, Inc.
A chemical associated with tuberculosis may substantially reduce the amount of damage sustained from a heart attack, a finding that could lead to new treatment for heart attack victims, according to a new study. The finding was made by two physician brothers in different disciplines who happened to discuss their individual research at a family gathering. Serendipity at its best.
A new UCLA study has revealed that many physicians may lack the training necessary to interpret CT scans and safely identify stroke patients who may benefit from "clot-busting" drug therapies.
UCLA researchers have isolated a unique naturally-occurring antibiotic from the femalse urinary and reproductive systems, which could lead to novel treatments for a variety of common infections including pelvic inflammatory disease, urinary tract and vaginal infections.
Benign, non-cancerous brain tumors, called meningiomas, can impair brain function and even kill. So UCLA medical researchers have begun testing a new form of chemotherapy to treat them.
A temporary heart device used by cardiac doctors at UCLA Medical Center saved a 24-year-old patient dying from heart failure. The cardiac-assist device avoided the need for an emergency heart transplant.
A UCLA orthopedic surgeon has developed a new technique to treat bone death in human hips that early results suggest may prevent the need for a total hip replacement. Called osteoregeneration, the procedure implants a capsule filled with bone-morphogenetic protein (BMP) that induces the body to grow new bone. Only UCLA offers BMP and the attendant procedure.